The Benefit of Sirolimus Maintenance Immunosuppression and Rabbit Antithymocyte Globulin Induction in Liver Transplant Recipients That Develop Acute Kidney Injury in the Early Postoperative Period

Table 1

Baseline demographics and secondary endpoints.

	Tacrolimus ()	Sirolimus ()
Recipient characteristics (mean ± SD unless otherwise specified)
Age at transplant (years)	53 ± 9	54 ± 9
Gender (male), (%)	118 (70)	19 (65)
Race (Caucasian), (%)	128 (76)	18 (62)
BMI (kg/m^2)	29 ± 5	29 ± 5
Primary disease of hepatitis C, (%)	83 (49)	9 (31)
Model for end-stage liver disease (MELD)	21 ± 6	23 ± 6
Pretransplant renal dysfunction	35 (21)^b	17 (59)^b
RRT during primary hospitalization, (%)	1 (1)	4 (14)
Primary hospitalization/length of stay (median days)	7^a,b	15^a,b
Mean duration of maintenance immunosuppression therapy (days)	361 ± 2	354 ± 6

Outlier detected using Grubb’s test.
between treatment groups.